Source: Therma Bright.
  • Therma Bright (THRM) has announced a C$6M private placement with institutional investors
  • The company will use the proceeds for general working capital purposes
  • It expects the placement to close on or about February 18, 2022
  • Therma Bright is a medical diagnostic and device technology company
  • Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share

Therma Bright (THRM) has announced a C$6M private placement with institutional investors.

The company will issue 20M units priced at $0.30 comprised of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share for $0.375 for five years following the issuance date.

The company will use the proceeds for general working capital purposes.

It expects the placement to close on or about February 18, 2022.

H.C. Wainwright & Co. is acting as the exclusive placement agent.

Therma Bright is a medical diagnostic and device technology company. It developed the AcuVid COVID-19 Rapid Antigen Saliva Test.

Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share as of 12:43 pm EST.

More From The Market Online

Dream Water Kids Sleep Gummies set for US summer debut

Delivra Health (TSXV:DHB) will launch a new line of kids sleep gummies under its Dream Water brand across the US market this June.

Embattled UAE orders SPARC AI’s GPS-free drone technology

SPARC AI to send its GPS-denied mobile drone navigation and targeting technology to a group working with the UAE Ministry of Defense.

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

RZOLV recycles silver from solar panel scraps

RZOLV Technologies (TSXV:RZL) achieved 89.8 per cent silver recovery rates in preliminary bench-scale tests on solar panel concentrate.